The UK-based company claims it is poised to dominate the bispecific antibody space in immuno-oncology through the application of its Modular Antibody Technology platform.

It has partnerships with several of the world's leading pharma companies including AbbVie, Bristol-Myers Squibb and Merck KGaA.